Form 4: Cytek Biosciences Executive Allen Poirson Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, reported the acquisition of shares through vesting of restricted stock units and the subsequent withholding of shares for tax obligations.

Summary

  • Allen Poirson, a Senior Vice President at Cytek Biosciences, filed a Form 4 detailing transactions related to his restricted stock units.
  • On November 18, 2024, Poirson acquired a total of 5,171 shares of common stock through the vesting of restricted stock units.
  • Simultaneously, 2,015 shares were withheld to cover tax obligations at a price of $6.03 per share.
  • After these transactions, Poirson directly owns 59,981 shares of Cytek Biosciences common stock.
  • The restricted stock units vest over four years, with varying portions vesting quarterly on specific dates.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation, which is a neutral event. The sentiment is slightly positive as it indicates the executive is receiving compensation in the form of stock, aligning their interests with shareholders.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the standard practice of granting restricted stock units to employees and executives as part of their compensation packages.

Comparison to Industry Standards

  • The vesting schedule of the restricted stock units is typical for the industry, with quarterly vesting over a four-year period.
  • The tax withholding process is standard practice for equity compensation, ensuring compliance with tax regulations.
  • Other companies in the biotech and life sciences sector, such as Illumina and Bio-Rad, also use similar equity compensation structures for their executives.

Stakeholder Impact

  • The transactions have a minor positive impact on shareholders as they align executive interests with company performance.
  • The vesting of restricted stock units is part of the executive's compensation package.

Key Dates

DateDescription
11/18/2024Date of the reported stock transactions, including vesting of restricted stock units and tax withholding.
11/20/2024Date the Form 4 was signed by Valerie Barnett, Attorney-in-Fact.

Keywords

Form 4, Cytek Biosciences, Stock Transactions, Restricted Stock Units, Insider Trading, Allen Poirson, Vesting, Tax Withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.